Predict your next investment

Venture Capital
foundationventure.com

See what CB Insights has to offer

Investments

16

Portfolio Exits

1

About Foundation Venture Capital Group

Foundation Venture Capital Group, LLC, established in March 2006 as an independent organization, invests exclusively in research at the University of Medicine and Dentistry of New Jersey (UMDNJ) by funding new life science companies.

Foundation Venture Capital Group Headquarters Location

120 Albany Street Tower II, 8th Floor

New Brunswick, New Jersey, 08901,

United States

(732) 235-5400

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Foundation Venture Capital Group News

Dr. Michael Johnson, CEO and Co-founder of Visikol, Invited to Speak...

Aug 23, 2018

Share Article Visikol began its journey in late 2012 as an idea at Rutgers University by Visikol Co-Founder Dr. Thomas Villani. Through support from advisors, mentors, the Rutgers Technology Transfer team and Foundation Venture Capital Group, Visikol Inc was launched a few years later. WHITEHOUSE STATION, N.J. (PRWEB)August 23, 2018 Visikol began its journey in late 2012 as an idea at Rutgers University by Visikol Co-Founder Dr. Thomas Villani. Through support from advisors, mentors, the Rutgers Technology Transfer team and Foundation Venture Capital Group, Visikol Inc was launched a few years later. Visikol’s path from an idea to a successful biotech company has been a circuitous path but was due in large part to the resources at Rutgers University, New Jersey-based investors and an ecosystem in New Jersey of mentors, advisors and experts. Since taking office, Governor Phil Murphy has been a strong advocate for building the New Jersey science, innovation and technology ecosystem by bringing together academic institutions and making it easier to bring an idea to life in the state. This focus is in response to many technology companies leaving the state or startups pursuing other states to grow their businesses in such as New York, Massachusetts or California. To support this effort, Governor Murphy recently announced the launch of the ResearchwithNJ.com initiative through which anyone can easily access the state’s academic experts. The centralization of this information in one database allows anyone to quickly find a technical expert in almost any field that can help them bring their idea to life. This database includes researchers and scientists from Princeton University, New Jersey Institute of Technology (NJIT), Stevens Institute of Technology, Rutgers University and Rowan University (Montclair State University will be joining the list soon). To further these efforts, on August 15th, Governor Murphy held a press conference at the Commercialization Center for Innovative Technologies in North Brunswick, NJ to announce the re-instatement of the state’s Commission on Science, Innovation and Technology. The commission will be reinstated and will be provided with $1 million in funding to launch initiatives aimed at re-establishing innovation in NJ. As the CEO of a company which began as an idea at Rutgers University and has matured into a profitable biotech business, Dr. Michael Johnson from Visikol was asked to speak at this press conference which was held a few hundred yards away from where the idea for Visikol was conceived. After an introduction from James Barrood, President of the NJ Tech Council, The Governor started the press conference by stressing the importance of fostering innovative and scientific companies and his major campaign goal of re-establishing New Jersey as the leading state for up and coming innovative companies like Visikol. The Governor then introduced Dr. Michael Johnson who spoke on behalf of Visikol and described their journey from Rutgers to maturing an innovative business within the state. Dr. Johnson began his speech by describing Visikol and their mission to accelerate drug discovery through the use of the machine learning, computer vision and advanced drug discovery tools that it has developed. Dr. Johnson explained that “there is currently a myth in the entrepreneurial community wherein a founder pulls themselves up by the bootstraps without the help of anyone else and wills their idea into existence.” However, it was described how this narrative is truly a myth and that launching a company is incredibly challenging and requires an ecosystem of experts, investors and resources. Visikol was only able to transform form an idea to a profitable and successful company through the help of New Jersey-based investors, the NJ EDA, Rutgers University, Foundation Venture Capital Group and a large group of advisors and mentors. For these reasons, Dr. Johnson expressed a sincere interest in the Governor’s efforts to launch ResearchwithNJ.com and to re-establish the Commission on Science, Innovation and Technology. Dr. Johnson explained how founders of a company seldom have all of the answers and by bringing together all of the experts in the state in one database it allows founders to much more easily find an expert to assist them with their endeavor.

Foundation Venture Capital Group Investments

16 Investments

Foundation Venture Capital Group has made 16 investments. Their latest investment was in OculoMotor Technologies as part of their Seed VC on July 7, 2019.

CBI Logo

Foundation Venture Capital Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/30/2019

Seed VC

OculoMotor Technologies

$0.5M

Yes

1

6/5/2019

Seed VC

KayoThera

$0.75M

Yes

1

6/8/2018

Unattributed VC

Actinobac Biomed

$1M

No

1

2/24/2016

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

9/17/2013

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/30/2019

6/5/2019

6/8/2018

2/24/2016

9/17/2013

Round

Seed VC

Seed VC

Unattributed VC

Seed VC

Unattributed

Company

OculoMotor Technologies

KayoThera

Actinobac Biomed

Subscribe to see more

Subscribe to see more

Amount

$0.5M

$0.75M

$1M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

Foundation Venture Capital Group Portfolio Exits

1 Portfolio Exit

Foundation Venture Capital Group has 1 portfolio exit. Their latest portfolio exit was Visikol on May 21, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/21/2021

Acquired

$99M

1

Date

5/21/2021

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

1

Foundation Venture Capital Group Team

2 Team Members

Foundation Venture Capital Group has 2 team members, including current Chief Executive Officer, George F. Heinrich.

Name

Work History

Title

Status

George F. Heinrich

Chief Executive Officer

Current

James M. Golubieski

President

Current

Name

George F. Heinrich

James M. Golubieski

Work History

Title

Chief Executive Officer

President

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.